Pyxis Oncology, Inc. — Investor Relations & Filings
Pyxis Oncology, Inc. is a clinical-stage company focused on developing next-generation therapeutics for difficult-to-treat cancers. The company's differentiated portfolio of clinical assets is centered on two primary modalities: antibody-drug conjugates (ADCs) and immuno-oncology (IO). Its ADC technology platform is designed to deliver potent cancer-killing agents directly to tumor cells for enhanced safety and efficacy. The immuno-oncology programs utilize monoclonal antibodies (mAbs) to mobilize the body's immune system to attack cancer cells by blocking tumor defense mechanisms and overcoming immune suppression. Pyxis Oncology is advancing its product candidates as both monotherapies and in combination with other therapies to improve outcomes for patients with solid tumors.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 10-Q | 2026-05-14 | English | |
| 8-K | 2026-05-14 | English | |
| ARS - Pyxis Oncology, Inc. (0001782223) (Filer) | 2026-04-30 | English | |
| DEF 14A - Pyxis Oncology, Inc. (0001782223) (Filer) | 2026-04-30 | English | |
| 8-K/A - Pyxis Oncology, Inc. (0001782223) (Filer) | 2026-04-30 | English | |
| 4 - Pyxis Oncology, Inc. (0001782223) (Issuer) | 2026-03-25 | English |
Browse filings by year
7 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
13 filings
| |||||
| 45988994 | 10-Q | 2026-05-14 | English | ||
| 45977153 | 8-K | 2026-05-14 | English | ||
| 39075634 | ARS - Pyxis Oncology, Inc. (0001782223) (Filer) | 2026-04-30 | English | ||
| 39073772 | DEF 14A - Pyxis Oncology, Inc. (0001782223) (Filer) | 2026-04-30 | English | ||
| 39069707 | 8-K/A - Pyxis Oncology, Inc. (0001782223) (Filer) | 2026-04-30 | English | ||
| 33043094 | 4 - Pyxis Oncology, Inc. (0001782223) (Issuer) | 2026-03-25 | English | ||
| 33043082 | 4 - Pyxis Oncology, Inc. (0001782223) (Issuer) | 2026-03-25 | English | ||
| 33042858 | 4 - Pyxis Oncology, Inc. (0001782223) (Issuer) | 2026-03-25 | English | ||
| 33012784 | 10-K - Pyxis Oncology, Inc. (0001782223) (Filer) | 2026-03-23 | English | ||
| 33012771 | 8-K - Pyxis Oncology, Inc. (0001782223) (Filer) | 2026-03-23 | English | ||
| 31693671 | SCHEDULE 13G/A Filing | 2026-02-09 | English | ||
| 31693670 | 8-K Filing | 2026-02-06 | English | ||
| 31693678 | 4 Filing | 2026-02-05 | English | ||
|
2025
2 filings
| |||||
| 13190750 | 8-K | 2025-12-18 | English | ||
| 13190751 | Regulatory Filings 2025 | 2025-12-10 | English | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
BriaCell Therapeutics Corp.
Developing targeted cellular immunotherapies using whole-ce…
|
BCTX | CA | Manufacturing |
|
BridgeBio Oncology Therapeutics, Inc.
Clinical-stage biopharma developing inhibitors for genetica…
|
BBOT | US | Manufacturing |
|
BridgeBio Pharma, Inc.
Develops transformative medicines for genetic diseases and …
|
BBIO | US | Manufacturing |
|
Brightgene Bio-Medical Technology Co., Ltd.
Research-driven developer of complex APIs, high-end generic…
|
688166 | CN | Manufacturing |
|
BRIGHT MINDS BIOSCIENCES INC.
Develops selective serotonin agonists for neurological and …
|
DRUG | US | Manufacturing |
|
BrightPath Biotherapeutics Co., Ltd.
A clinical-stage biopharma company developing cancer immuno…
|
4594 | JP | Manufacturing |
|
Brii Biosciences Limited
Developing first-in-class therapies targeting infectious an…
|
2137 | KY | Manufacturing |
|
BRISTOL MYERS SQUIBB CO
A global biopharmaceutical company that discovers, develops…
|
BMY | US | Manufacturing |
|
BROOKS LABORATORIES LIMITED
Pharmaceutical manufacturer specializing in CRAMS and diver…
|
BROOKS | IN | Manufacturing |
|
BUKWANG PHARMACEUTICAL IND CO.,LTD
An R&D-focused company developing drugs for CNS disorders a…
|
003000 | KR | Manufacturing |
Pyxis Oncology, Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/33976/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=33976 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=33976 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=33976 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 33976}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Pyxis Oncology, Inc. (id: 33976)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.